8/4/2019 Project of Shalini
1/15
A Project report
On
Recruitment& Selection at Mankind pharma ltd.
Submitted to
Indira Institute of career study
Mankind Pharma ltd.
Shalini Singh (2010-2012)
8/4/2019 Project of Shalini
2/15
Acknowledgment
The joy of ingenuity!!! This is doubtlessly what this project is about. Before getting to brass
tacks of things. I would like to add a heartfelt word for the people who have helped me in
bringing out the creativeness of this project. To commence with things I would like to take this
opportunity to gratefully and humbly thank to Ms Mandvi Vaid , Project guide, Mankind pharma
ltd., Delhi, for being appreciative enough by giving me an opportunity to undertake this project
in Mankind pharma ltd. Respected guide Mr. M.V. Kulkarni Indira school of career study, Pune
for his undeterred guidance for the completion of the report.
My parents need special mentions here for their constant support and love in my life.
I also thank my friends and well wishers, who have provided their whole hearted support to mein this exercise. I believe that this Endeavor has prepared me for taking up new challenging
opportunities in future.
8/4/2019 Project of Shalini
3/15
Table of contents
8/4/2019 Project of Shalini
4/15
Executive summary-
In todays rapidly changing business environment, organizations have to respond quickly to
requirements for people. The Financial market has been witnessing growth which is manifold for
last few years. Many private players have entered the economy thereby increasing the level of
competition. In the competitive scenario it has become a challenge for each company to adopt
practices that would help the organization stand out in the market. The competitiveness of a
company of an organization is measured through the quality of products and services offered to
customers that are unique from others. Thus the best services offered to the consumers are result
of the genius brains working behind them. Human Resource in this regard has become an
important function in any organization. All practices of marketing and finances can be easily
emulated but the capability, the skills and talent of a person cannot be emulated. Hence, it is
important to have a well-defined recruitment policy in place, which can be executed effectively
to get the best fits for the vacant positions. Selecting the wrong candidate or rejecting the right
candidate could turn out to be costly mistakes for the organization. Therefore a recruitment
practice in an organization must be effective and efficient in attracting the best manpower.
With largest number of life pharmaceutical policies in force in the world, pharmaceutical
happens to be a mega opportunity in India. Its business is growing at 15-20% annually and
presently is of the order of Rs. 450m. Together with banking sector it adds about 7% to the GDP.
Like in the case of BPOs, Pharmaceutical sector too faces the problem of attrition. Thus,
recruitment is an ongoing process carried through out the year. The project is based on the study
of recruitment process. The various recommendations suggested have been the result of the
study. The idea is to generate ways of dealing with high attrition and making hiring process
manageable and efficient.
8/4/2019 Project of Shalini
5/15
Part 1
Company Profile
:-
8/4/2019 Project of Shalini
6/15
History of Mankind pharma Ltd. -
Established in 1995 with a capital of 50 lakhs, Mankind at present is a leading pharmaceutical
company of India. Our Goal is to help the community to lead healthy life through two parallelobjectives: formulating, developing & commercializing medicines, and delivering affordable &
accessible medication that satisfy urgent medical needs.
Mankind has out-performed the Indian Pharmaceutical industry by growing at the rate of 60%
year after year. It is among the top 5 fastest growing Pharma companies of India as per ORG-
IMS. It has achieved the turnover of Rs.1650 Cr in 2010-2011.
It is a fully integrated pharmaceutical company having pan India presence with a comprehensive
network of 62 C&F agents & 6000 Stockists. It is ranked 8th in India as per IMS-Health 2011and as per ORG-IMS Prescription / Doctor / Month audit of Feb.2011, it is ranked 1st in India.
The strong portfolio of businesses, geographies and products provide us the strategic benefits of
integration that allow it to perform best in an increasingly competitive market.
It has a strong market presence in Antibiotics, Antifungal, Gastrointestinal, NSAIDs,
Anthelmintics, Cardiovascular, Dermal and Erectile Dysfunction categories. Numbers of our
products are at top 5 positions as per ORG-ims.
8/4/2019 Project of Shalini
7/15
The Various Divisions and Companies under Mankind Group-
Discovery Mankind
Incepted in the year 2003 as a marketing division of Mankind Pharma, today Discovery Mankind
is having a wide product range to treat diabetic metabolic disorder. It is also having products inantibiotic, GI , anti fungal & lifestyle segments.
Life star Pharma
Launched in the year 2005 as a group company. Life star offers comprehensive range of products
in ophthalmic & dermal segment. It is also having product range in antibacterial, GI & other
segments.
Special Mankind
Special Mankind launched in January 2007 is poised to meet OTC requirements. This division is
pioneer in launching of premium category condoms, toothbrush, sanitary napkins & sweeteners.
Future Mankind
Future Mankind was positioned in the year 2007 to cater the growing demand of acute & chronic
therapeutic segments. In Future Mankind orthopedic drugs along with GI & other specialty is
comprehensively represented in line to Mankind group philosophy.
Magnet Labs
With purpose to cater the growing market of neuropsychological segment Mankind acquired
Magnet Labs in the year 2007. It is pioneer in formulations of acute & chronic psychiatric
segments.
Vet Mankind
The strong impact of the philosophy of Serving Life lead to the foundation of this division in
the year 2007 to serve the Indian animal husbandry needs. It comprises veterinary products in
Antibacterial, Nutritionals, Reproductive, NSAIDs , Digestive categories etc.
Pet Mankind - Launched in 2011 to cater to the needs of the pets.
8/4/2019 Project of Shalini
8/15
Milestones -
2011
Coming up with R&D and Learning & Development Centre in NCR.
2010
1) Successfully launched OTC products like Prega News, Addiction, Unwanted-72, Don't
Worry.
2) Spread the wings globally with the launch of Mankind in Sri Lanka.
3) Established State-of-Art manufacturing Unit for liquid dosages & tablets.
2008
1) Achieved 40% growth.2) 1 st rank all over INDIA as per Prescription/Doctor/Month.
3) 8 th Rank as per IMS-HEALTH
4) 21 brands at No. 1 position & 14 brands at No. 2 Position as per ORG-ims & stockist
Secondary Audit.
5) 53 brands in top 5 position as per ORG-ims & stockiest Secondary Audit.
2007
1) Launched Future Mankind, Special Mankind and Vet Mankind.2) Acquired Magnet Labs Pvt. Ltd.
3) Christ capital become an investor partner.
4) Awarded "Emerging Company of the year" by Indian Express Pharma Pulse.
5) Tied up with Roche Diagnostic for the marketing of product Accu chek Go .
2006
1) Established Injectable state-of-the-art unit at Paonta sahib (HP).
2) Group Turnover surged up to Rs.512 Cr.
2005
1) Celebrated Decade of trust with medical fraternity.
2) Launched Lifestar Pharma,
3) Awarded by Indian Express Pharma Pulse for Overall Best Performance .
8/4/2019 Project of Shalini
9/15
2007
1) Company established its operations all over India.
2) Launched new division Discovery Mankind .
Mission
To deliver medicines that enable patients to live healthier, happier and more active lives.
Vision-
To be the No.1 Pharma Company of India by 2015
To mark the presence in former CIS Countries, South East Asia, Africa and Latin
America.
8/4/2019 Project of Shalini
10/15
Infrastructure-
The Manufacturing Units are at Paonta Sahib-HP
Manufacturing Unit-1
To meet the ever increasing demand of the products, Mankind has its state-of-the-art Injectablemanufacturing unit at Paonta sahib (Himachal Pradesh).The unit is designed as per the USFDA(U.S. Food and Drug Administration) guidelines. The production capacity of 60 million ampoulesand 30 million vials is on a single shift basis.
Manufacturing Unit-11-
Is under Construction but soft gelatin capsules and liquid Syrups are manufactured here.
Manufacturing Unit-111
It is designed as per Camp. Capacity of plant is 6.0 Crore tablets / month in a single sift.Plant ismade for solid dosage form only with all regulatory aspects . Currently we are manufacturingDolokind plus tabs, Losakind group, T-98, Nobel group, Pentakind, Nurokind -G, Lipikind 10/20and many other products are in pipeline for manufacturing
8/4/2019 Project of Shalini
11/15
Mankind Products-
There are many (OTC )products that are given below: (Over the Counter)
1. ANTI DANDRUFF
2. CONDOMS
3. ED DRUG
4. ORAL CONTRACEPTIVE
5. PREGNANCY DETERMINATION KIT SWEETENER
6. ADICTION DEODORANT
Animal Product
1. ANTHELMINTICS
2. ANTI-INFLAMMATORY & ANALGESICS
3. ANTIBACTERIALS
4. ANTIPROTOZOAL
5. APPETITE STIMULANT / DIGESTIVES
6. FERTILITY ENHANCER
http://www.mankindpharma.com/view_product.php?view=3&divID=85http://www.mankindpharma.com/view_product.php?view=3&divID=81http://www.mankindpharma.com/view_product.php?view=3&divID=84http://www.mankindpharma.com/view_product.php?view=3&divID=86http://www.mankindpharma.com/view_product.php?view=3&divID=83http://www.mankindpharma.com/view_product.php?view=3&divID=82http://www.mankindpharma.com/view_product.php?view=2&divID=79http://www.mankindpharma.com/view_product.php?view=2&divID=72http://www.mankindpharma.com/view_product.php?view=2&divID=78http://www.mankindpharma.com/view_product.php?view=2&divID=73http://www.mankindpharma.com/view_product.php?view=2&divID=75http://www.mankindpharma.com/view_product.php?view=2&divID=77http://www.mankindpharma.com/view_product.php?view=3&divID=81http://www.mankindpharma.com/view_product.php?view=3&divID=84http://www.mankindpharma.com/view_product.php?view=3&divID=86http://www.mankindpharma.com/view_product.php?view=3&divID=83http://www.mankindpharma.com/view_product.php?view=3&divID=82http://www.mankindpharma.com/view_product.php?view=2&divID=79http://www.mankindpharma.com/view_product.php?view=2&divID=72http://www.mankindpharma.com/view_product.php?view=2&divID=78http://www.mankindpharma.com/view_product.php?view=2&divID=73http://www.mankindpharma.com/view_product.php?view=2&divID=75http://www.mankindpharma.com/view_product.php?view=2&divID=77http://www.mankindpharma.com/view_product.php?view=3&divID=858/4/2019 Project of Shalini
12/15
7. HORMONES
8. NUTRITIONALS
9. UTERINE TONIC
Growth Scenario in 2010-
India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is
14th in terms of value. Between September 2008 and September 2009, the total turnover of India's
pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26
billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and
Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$
10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is
estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out this in
our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical
Market Trends 2010
Leading Pharmaceutical Companies-
In the domestic market, Cipla retained its leadership position with 5.27 per cent share. Ranbaxy
followed next. The highest growth was for Mankind Pharma (37.2%). Other leading companies in
the Indian pharma market in 2010 are
Sun Pharma (25.7%) Abbott (25%) Zydus Cadila (24.1%)
http://www.mankindpharma.com/view_product.php?view=2&divID=76http://www.mankindpharma.com/view_product.php?view=2&divID=80http://www.mankindpharma.com/view_product.php?view=2&divID=74http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.mankindpharma.com/view_product.php?view=2&divID=76http://www.mankindpharma.com/view_product.php?view=2&divID=80http://www.mankindpharma.com/view_product.php?view=2&divID=74http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/articles/indian-pharmaceutical-industry.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.htmlhttp://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-market-trends-2010.html8/4/2019 Project of Shalini
13/15
Alkem Laboratories (23.3%) Pfizer (23.6 %) GSK India (19%) Piramal Healthcare (18.6 %) Lupin (18.8 %)
Future Prospects-
Characteristics of Indian Pharmaceutical The Indian pharmaceuticals market is expected to reach
US$ 55 billion in 2020 from US$ 12.6 billion in 2009. This was stated in a report title "India
Pharma 2020: Propelling access and acceptance, realizing true potential" by McKinsey &
Company. In the same report, it was also mentioned that in an aggressive growth scenario, the
pharma market has the further potential to reach US$ 70 billion by 2020.
Due to increase in the population of high income group, there is every likelihood that they will open
a potential US$ 8 billion market for multinational companies selling costly drugs by 2015. This was
estimated in a report by Ernst & Young. The domestic Pharma market is estimated to touch US$ 20
billion by 2015. The healthcare market in India to reach US$ 31.59 billion by 2020. The sale of all
types of pharmaceutical drugs and medicines in the country stands at US$ 9.61 billion, which is
expected to reach around US$ 19.22 billion by 2012. Thus India would really become a lucrative
destination for clinical trials for global giants. There was another report by RNCOS titled"Booming Pharma Sector in India" in which it was projected that the pharmaceutical formulations
industry is expected to prosper in the same manner as the pharmaceutical industry. The domestic
formulations market will grow at an annual rate of around 17% in 2010-11, owing to increasing
middle class population and rapid urbanization.
http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.htmlhttp://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-drugs/pharmaceutical-finished-formulations.html8/4/2019 Project of Shalini
14/15
Industry-
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It
has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control
70% of the market with market leader holding nearly 7% of the market share. It is an extremely
fragmented market with severe price competition and government price control.
The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs,
drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and
injectable. There are about 250 large units and about 8000 Small Scale Units, which form the core
of the pharmaceutical industry in India (including 5 Central Public Sector Units). These units
produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption
by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for
production of pharmaceutical formulations. Following the de-licensing of the pharmaceutical
industry, industrial licensing for most of the drugs and pharmaceutical products has been done away
with. Manufacturers are free to produce any drug duly approved by the Drug Control Authority.
Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of
production, low R&D costs, innovative scientific manpower, strength of national laboratories and
an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and
research capabilities, supported by Intellectual Property Protection regime is well set to take on t
http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/http://www.pharmaceutical-drug-manufacturers.com/pharmaceutical-industry/8/4/2019 Project of Shalini
15/15
Top Related